CypMaster™ CYP Phenotyping Kit

Identifies specific CYP450 enzymatic contributions to drug biotransformation using a comprehensive panel of isoform-selective chemical inhibitors.

CypMaster™

ADME

Metabolism

The CypMaster™ CYP Phenotyping Kit provides a high-efficiency in vitro solution for reaction phenotyping. By utilizing a panel of highly selective, mechanism-based inhibitors, this system accurately quantifies the fractional contribution of major CYP isoforms to total hepatic metabolism, offering a superior alternative to recombinant enzymes for predicting clinical drug clearance.

Mechanism-Based Precision: Employs rigorously validated, isoform-specific inhibitors that ensure irreversible and highly selective enzymatic inactivation for accurate reaction phenotyping.
Biorelevant Matrix: Utilizes pooled human liver microsomes to provide a physiologically relevant environment containing natural ratios of CYP450 and reductase.
Optimized Experimental Control: Includes standardized incubation reagents and NADPH regeneration components, reducing assay variability and streamlining complex LC-MS/MS metabolic mapping.
Regulatory Compliance: Designed to meet rigorous guidelines for in vitro drug-drug interaction studies and metabolic stability assessments.

Determines which CYP450 enzymes drive drug clearance to predict patient-specific variability and potential clinical drug-drug interaction risks.

Lead optimization, preclinical ADME characterization, and regulatory-standard in vitro drug interaction and metabolism studies.

Reaction phenotyping, determining fm values for major CYPs, identifying metabolic liabilities, ADME profiling studies, and evaluating inhibitory potentials within pooled microsomal models.

Internal performance validation using reference standards under defined assay conditions.

Seven major human liver CYP450 isoforms

Human liver microsomes, enzyme-inactivated microsomal preparations, and matched control microsomes.

Quantitative

Pharmacokinetics (ADME), drug-drug interactions (DDI), oncology therapeutics, clinical pharmacology, etc.

Quantitative determination of isoform-specific metabolic contribution and percentage of enzymatic inhibition via metabolite analysis.

Human

Quantitative

Upon receipt, store the kit in accordance with the storage conditions specified in the product manual.

Avoid repeated freeze-thaw cycles. During use, minimize the time components are exposed to room temperature and return them promptly to -20°C; storage after handling. Do not store at elevated temperatures for extended periods.

12 months under recommended storage conditions to ensure optimal performance.

For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.

For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.

Shipped on ice under temperature-controlled conditions.

Cytochrome P450 enzymes are the primary drivers of Phase I oxidative metabolism. Identifying the specific isoforms involved in drug clearance is essential for managing patient safety and predicting inter-individual variability.

CYP450 enzymes catalyze the oxidation of lipophilic xenobiotics within the hepatic endoplasmic reticulum. This pathway requires electrons from NADPH, transferred via NADPH-cytochrome P450 reductase, to facilitate systemic drug detoxification.